More news: Health/Surgery
Agency / Source: Dentsu

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Dentsu Announces its Corporate Venture Capital Fund Dentsu Ventures Investment in Grail - Dentsu, Inc. announced that Dentsu Ventures Global Fund I (hereinafter
Dentsu Announces its Corporate Venture Capital Fund Dentsu Ventures Investment in Grail

 

PRZOOM - /newswire/ - Tokyo, Japan, 2017/06/13 - Dentsu, Inc. announced that Dentsu Ventures Global Fund I (hereinafter "Dentsu Ventures") has made an investment in Grail, Inc. - Grail.com / Dentsu-V.com. Tokyo: 4324

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Dentsu, Inc. (President & CEO: Toshihiro Yamamoto; Head Office: Tokyo; Capital: 74,609.81 million yen) announced today that Dentsu Ventures Global Fund I (hereinafter "Dentsu Ventures"), the Company's corporate venture capital fund, has made an investment in Grail, Inc. (Head Office: Menlo Park; CEO: Jeff Huber; hereinafter "Grail"), a developer of blood testing techniques for the early detection of cancer located in the United States.

Grail (grail.com), a life science company whose mission is the early detection of cancer, utilizes proprietary sequencing (DNA sequence information reading) technologies, large-scale clinical trials and cutting-edge computer science and data science in an effort to develop and verify blood testing techniques for the early detection of cancer, when it can be cured. To this end, Grail has raised more than US$900 million of necessary funding through a Series B financing round.

Dentsu Ventures is participating in the Series B financing round and plans to support Grail's partnership strategy in Japan. The Dentsu Group will establish alliances between clients and partner companies to encourage the practical application of Grail technologies in Japan. In the future, we also want to contribute to the adoption of testing aimed at the early detection of cancer and increased screening rates.

Dentsu Ventures (dentsu-v.com) is a fund established in April 2015 to realize open innovation across the Dentsu Group through collaborations and investments in start-up companies. The total amount of this fund has been increased from the existing 5 billion to 10 billion yen to expand these activities. We will continue to invest globally, and going forward, we plan to increase investments in the Asia-Pacific region, including Japan, as well as in the European region. We will also enhance our staff to support investees and further strengthen our joint business development structure with investees.

Profiles of Grail and Dentsu Ventures are provided below:

Profile of Grail
Company Name: Grail, Inc.
Location: Menlo Park, California, U.S.A.
Representative: Jeff Huber, CEO
Line of Business: Development of blood testing techniques for the early detection of cancer.

Profile of Dentsu Ventures
Name: Dentsu Ventures Global Fund I
Total Fund Capital: 10 billion yen
Date of Establishment: April 2015
Period of Operation: Ten-year period from April 2015 until March 2025
Investment Regions: Global investments with a focus on the U.S.A., Europe, Japan and Asia
Investment Stages: Balanced, wide-ranging investments with the focus on seed and early stage investments, but also including mid-stage and later-stage investments
Investment Areas: (1) Areas that can change the marketing and communication business in a broad sense, (2) New areas other than the above that have a high potential for innovation.


Investment-related enquiries:
Dentsu Ventures
E-mail: info[.]dentsu-v.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Dentsu

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Dentsu Announces its Corporate Venture Capital Fund Dentsu Ventures Investment in Grail

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Shusaku Kannan - Dentsu.co.jp 
+81 3-6216-8042 s.kannan[.]dentsu.co.jp
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Dentsu securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Dentsu / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024 Says Frost & Sullivan
Komodo Health Lauded by Frost & Sullivan for Empowering Healthcare Stakeholders with Dynamic Real-world Evidence Solutions
NEC Solution Innovators Establishes 'FonesLife,' A Healthcare Business Company that Contributes to Extending Healthy Life Expectancy
Frost & Sullivan Recognizes DrFirst for Solutions Providing Secure Communication, Collaboration, and Real-Time Access to Patient
The American Psychiatric Association Selects Wiley to Publish its Open Access Journal Psychiatric Research and Clinical Practice
EHR Investments Increase as Governments and Healthcare Authorities Focus on Interoperability Finds Frost & Sullivan
South Carolina’s Humimic Medical Arming Healthcare Workers for the COVID-19 War
SCBIO Executive Erin Ford Appointed to South Carolina District Export Council for 2020-2021
University of the Ryukyus and NEC Discover a Novel Diagnostic Biomarker for Acute Adult T-cell Leukemia/lymphoma
Change Healthcare Recognized by Frost & Sullivan for Accelerating Claims Processing with its Intelligent Healthcare Network™ Blockchain Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  RightITnow, Inc.







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today